Latest news with #Tolvaptan
Rhyl Journal
20-06-2025
- Health
- Rhyl Journal
‘Loving, caring' Rhuddlan mother will be ‘hugely missed'
Ann Winifred Sellwood, of Highlands Road in Rhuddlan, died aged 72 at the Bodelwyddan hospital on December 14, 2023. At the resumption of the inquest into her death, held in Ruthin today (June 20), John Gittins, senior coroner for North Wales East and Central, gave a medical cause of death of pneumonia as a result of a fall with rib fractures and chronic pulmonary disease and contributing pulmonary heart disease. Mrs Sellwood was born in Accrington on December 8, 1951, and was a retired nurse who had also run a pub with her husband Paul. Her son Paul told the inquest his mother had 'loved people', and described her as a 'great, loving, caring' person who 'looked after other people before herself'. In the five years before her death, her health had declined – she had arthritis in her back which caused mobility issues and 'made her introverted and reserved over time'. She also had a history of chronic obstructive pulmonary disease (COPD), and was on medication including an inhaler. The inquest was told she had suffered some falls in the months prior to her death, and had been admitted to Ysbyty Glan Clwyd in October (7-11), November (1-10) and again between November 25 and December 4. This was because of low sodium levels, and these levels had dropped during hospital visits. Upon her second admission to Glan Clwyd, her sodium levels were again low, with a cut on her thigh evidence of a fall four weeks prior. Dr Sanghamitra Chakrabarti, a consultant in acute geriatrics who treated Mrs Sellwood, said they started her on steroid replacement medication, which gradually saw her sodium levels improve. She was discharged on November 10 having 'never complained of chest pain or cardiac problems during this admission', and was given medication to take twice a day. However, between this and her third admission, her husband said she had started to deteriorate after around a week out of hospital. Her third admission to hospital came after another fall, and her sodium levels decreased for several days before a diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH), which causes sodium levels to be lower. Dr Aye Nyunt, a consultant in general surgery, said Mrs Sellwood's sodium levels increased on December 3 and 4, and she was discharged again and prescribed Tolvaptan, which treats low sodium in the blood. READ MORE: Woman who died in crash on A548 coast road is named Abergele man died after falling from mountain range in Eryri Despite there being no plan to discharge her on December 1 (a Friday), Mrs Sellwood was moved to a different ward by December 4 in anticipation of her discharge. Dr Nyunt described Mrs Sellwood as 'mobilising independently, eating and drinking' on December 4, and was not aware of the family's concerns regarding the decision to discharge her at the time. She said Mrs Sellwood's sodium levels were 'safe enough' to be discharged, with her GP to monitor these levels weekly. Her husband Paul said the family 'disagreed on a number of occasions when told she was good to go home' and were 'given medication and not told how to use it', which he told the inquest was 'very upsetting'. Her behaviour became 'more erratic' after the third discharge from hospital, and she fell at home in the intervening period – her son Paul described her eating habits as 'really abnormal' and 'like she was starving'. He said she was not 'sound of mind' at that time, and that he felt they 'should have taken her back' to Glan Clwyd again. On December 8, she had blood tests done at her GP surgery, but the results, which show low sodium levels, did not come back until the following Monday (December 11). Later that day, Mrs Sellwood fell against a worktop at home and was 'screaming in absolute agony', and in the early hours of December 9 was re-admitted to Ysbyty Glan Clwyd. A CT scan was done on December 10, which showed rib fractures to her right side, but despite further monitoring and investigation, she died on December 14. Dr Huyam Abdalsalam, a consultant pathologist at Ysbyty Glan Clwyd, said Mrs Sellwood showed signs of cardiac disease and pneumonia, with the latter considered the terminal event. Her medical cause of death was pneumonia with contributing rib fractures and underlying smoking and heart disease. Mr Gittins gave a narrative conclusion, and confirmed a medical cause of death of pneumonia as a result of a fall with rib fractures and chronic pulmonary disease and contributing pulmonary heart disease. He said: 'On December 8 dec the deceased had a blood test at her GP surgery. 'When analysed, neither she nor her family were made aware of the results. 'That evening, she collapsed in her bedroom and sustained rib injuries which resulted in her death on December 14. Mr Gittins said that there were 'concerns that need addressing', with the health board set to investigate and conduct enquiries into how GP test results were conveyed between departments. Addressing Mrs Sellwood's family, he expressed his condolences on the 'loss of a lady who is hugely missed'.
Time of India
13-05-2025
- Business
- Time of India
Lupin launches generic version of kidney disorder treatment drug in US
Pharma major Lupin Ltd on Tuesday said it has launched the generic version of Tolvaptan tablets used to slow kidney function decline in the US market , following the recent approval received from the country's health regulator. The company has launched Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg in the US, after receiving the approval from the US Food and Drug Administration ( USFDA ). #Operation Sindoor The damage done at Pak bases as India strikes to avenge Pahalgam Why Pakistan pleaded to end hostilities Kashmir's Pahalgam sparks Karachi's nightmare "Lupin holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity," Lupin said in a statement. Tolvaptan tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company, Ltd, and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), it added. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like She is Revealing Her Secret Strategy in Commodity Trading TradeWise Learn More Undo by Taboola by Taboola Lupin CEO Vinita Gupta said the launch of Tolvaptan Tablets in the US will provide ADPKD patients with increased access to high-quality treatment options.
Business Upturn
13-05-2025
- Business
- Business Upturn
Lupin launches Tolvaptan tablets in the US for ADPKD treatment
By Aman Shukla Published on May 13, 2025, 12:00 IST Lupin Limited, a global pharmaceutical company, has announced the launch of its generic Tolvaptan Tablets in the United States following approval from the U.S. Food and Drug Administration (FDA). The product is available in multiple strengths: 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. Tolvaptan Tablets are the generic equivalent of Jynarque®, a brand-name medication developed by Otsuka Pharmaceutical Company, Ltd. The drug is used to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Lupin has secured exclusive first-to-file status for the generic version of Tolvaptan, which grants the company 180 days of marketing exclusivity in the U.S. market. This exclusivity period allows Lupin to be the only generic manufacturer selling the product during that time. Vinita Gupta, CEO, Lupin, stated, 'We are pleased to announce the launch of Tolvaptan Tablets in the U.S. to provide ADPKD patients with increased access to high-quality treatment options.' According to available data, Jynarque® recorded estimated U.S. sales of approximately $1.467 billion for the fiscal year ending December 31, 2024. The launch of Tolvaptan Tablets is part of Lupin's strategy to expand its portfolio of affordable treatments in the U.S. pharmaceutical market. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
The Hindu
24-04-2025
- Business
- The Hindu
U.S. FDA grants approval for Lupin's generic Tolvaptan tablets
Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for Tolvaptan tablets of different strengths. It is the exclusive first-to-file for this product and consequently eligible for 180 days of generic drug exclusivity. The product will be manufactured at its Nagpur facility and launched soon, Lupin said on Thursday. The approved product is bioequivalent to Otsuka Pharmaceutical Company's Jynarque Tablets 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease. Tolvaptan tablets had an estimated annual sale of $1,467 million in the U.S. during 2024. CEO Vinita Gupta said the development marks 'a significant entry into the nephrology segment' for the company.
&w=3840&q=100)
Business Standard
24-04-2025
- Business
- Business Standard
Lupin gets USFDA nod for generic kidney disease treatment drug Tolvaptan
Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of Tolvaptan tablets indicated for a certain type of kidney disease. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, Lupin said in a regulatory filing. These are bioequivalent to Jynarque tablets in the same strengths of Otsuka Pharmaceutical Company Ltd, it added. "Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Nagpur facility and will be launched soon," the company said. Commenting on the approval, Lupin CEO Vinita Gupta said,"This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally." Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), it said. These tablets had an estimated annual sale of $1,467 million in the US in 2024.
